The federal Project Grant award R43AI174490 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $291,697 to CFD Research Corporation to develop a novel class of antibiotics against the drug-resistant bacterium Neisseria gonorrhoeae. The project aims to optimize a promising natural product compound discovered by the company, evaluate its in vivo efficacy in a mouse model, and elucidate its mechanism of action. This work is intended to produce an optimized lead compound for further preclinical development as a new treatment for drug-resistant gonorrhea, which is considered a highest threat level by the CDC due to its ability to rapidly acquire resistance. The award covers a project period from April 2024 through March 2026.
Generated 3/4/25, 6:38 AM